FibroBiologics Granted Patent for Regeneration of Cartilage-Type Cells by the Australian Patent Office
April 11 2024 - 9:31AM
FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a
clinical-stage biotechnology company with 150+ patents issued and
pending with a focus on the development of therapeutics and
potential cures for chronic diseases using fibroblasts and
fibroblast-derived materials, announced the issuance of a patent
from the Australian Patent Office (Patent Number 2017207445)
covering the proprietary method using a particular cellular blend
for the regeneration of chondrocytes or cartilage-type cells.
Cartilage is a vital connective tissue that
provides cushioning, support, and flexibility to the joints
including the spine. Cartilage tissue, due to a lack of
vascularization, has a limited capacity to heal when damaged,
potentially leading to pain, inflammation, and loss of function in
the affected joint. FibroBiologics’ fibroblast cell-based
technology offers a potential solution to regenerate cartilage
tissue and restore its function, by using a natural and
biocompatible cellular blend that can adapt to the specific needs
of the target tissue.
“The awarding of this patent recognizes the
novelty and utility of our method for cartilage regeneration using
fibroblast and other cell types. It strengthens our position in
fibroblast cell therapy and regenerative medicine,” said Founder
& Chief Executive Officer of FibroBiologics, Pete O’Heeron.
“Discs are complex structures that act as shock
absorbers between the bones and require a delicate balance of
mechanical, biochemical, and cellular factors to maintain health
and function. Disc degeneration is a multifactorial process that
involves the loss of proteoglycans and chondrocytes from the
nucleus pulposus. Our fibroblast cell-based technology has the
potential to replenish the nucleus pulposus with its essential
secreted components, facilitating cell differentiation and
modulating the inflammatory and degenerative environment of the
disc. We believe that the methodology described in our issued
patent has the potential to offer a long-lasting and minimally
invasive solution for disc repair and regeneration,” added Chief
Scientific Officer of FibroBiologics, Hamid Khoja, Ph.D.
For more information, please visit FibroBiologics’
website or email FibroBiologics at:
info@fibrobiologics.com.
Cautionary Statement Regarding
Forward-Looking Statements
This communication contains "forward-looking
statements" as defined in the Private Securities Litigation Reform
Act of 1995. Forward-looking statements include information
concerning the potential of fibroblasts and fibroblast cell-based
technology to regenerate cartilage tissue, restore its function,
and offer a long-lasting and minimally invasive solution for disc
repair and regeneration, modulate the inflammatory and degenerative
environment of the disc, and offer clinical benefits for patients.
These forward-looking statements are based on FibroBiologics'
management's current expectations, estimates, projections and
beliefs, as well as a number of assumptions concerning future
events. These forward-looking statements are not guarantees of
future performance, conditions or results, and involve a number of
known and unknown risks, uncertainties, assumptions and other
important factors, many of which are outside FibroBiologics'
management's control, that could cause actual results to differ
materially from the results discussed in the forward-looking
statements, including those set forth under the caption "Risk
Factors" and elsewhere in FibroBiologics' annual, quarterly and
current reports (i.e., Form 10-K, Form 10-Q and Form 8-K) as filed
or furnished with the SEC and any subsequent public filings. Copies
are available on the SEC's website, www.sec.gov. These risks,
uncertainties, assumptions and other important factors include, but
are not limited to: (a) risks related to FibroBiologics' liquidity
and its ability to maintain capital resources sufficient to conduct
its business; (b) expectations regarding the initiation, progress
and expected results of our R&D efforts and preclinical
studies; (c) the unpredictable relationship between R&D and
preclinical results and clinical study results; and (d) the ability
of FibroBiologics to maintain and defend its intellectual property.
Forward-looking statements speak only as of the date they are made.
Readers are cautioned not to put undue reliance on forward-looking
statements, and FibroBiologics assumes no obligation and, except as
required by law, does not intend to update, or revise these
forward-looking statements, whether as a result of new information,
future events, or otherwise. FibroBiologics gives no assurance that
it will achieve its expectations.
About FibroBiologics
Based in Houston, FibroBiologics is a cell
therapy and regenerative medicine company developing a pipeline of
treatments and seeking potential cures for chronic diseases using
fibroblast cells and fibroblast-derived materials. FibroBiologics
holds 150+ US and internationally issued patents/patents pending
across various clinical pathways, including disc degeneration,
orthopedics, multiple sclerosis, wound healing, reversing organ
involution, and cancer. FibroBiologics represents the next
generation of medical advancement in cell therapy. For more
information, visit www.FibroBiologics.com.
General
Inquiries:info@fibrobiologics.com
Investor Relations:Nic Johnson or Harrison
Seidner, Ph.D.Russo
Partners212-845-4242fibrobiologicsIR@russopr.com
Media Contact:Liz PhillipsRusso Partners(347)
956-7697Elizabeth.phillips@russopartnersllc.com
FibroBiologics (NASDAQ:FBLG)
Historical Stock Chart
From Apr 2024 to May 2024
FibroBiologics (NASDAQ:FBLG)
Historical Stock Chart
From May 2023 to May 2024